Indonesia pushes for vaccine independence with new typhoid jab

Indonesia is bolstering its national vaccine independence with the launch of Bio-TCV, a typhoid conjugate vaccine developed through a significant collaboration between academic institutions, industry, and the government. This innovative vaccine represents a crucial step in the nation's healthcare development, showcasing Indonesia's capability to transform research findings into tangible public health products.

The development of Bio-TCV is a testament to the synergy between the Faculty of Medicine at the University of Indonesia (FKUI), Cipto Mangunkusumo Hospital (RSCM), and the state-owned pharmaceutical company PT Bio Farma. This collaborative effort underscores a new era in Indonesian healthcare, where research, industry, and government operate within a unified innovation ecosystem, moving away from isolated efforts.

“

Bio-TCV is not just an innovative conjugate typhoid vaccine by the nation's children, but it is a marker that Indonesia is beginning to enter a new phase of health development.

Bio-TCV is designed to provide active immunization against typhoid fever, caused by Salmonella typhi. It is suitable for individuals from six months of age to adults, thereby strengthening national immunization programs and extending protection to vulnerable populations. The vaccine is also slated for international market entry through the World Health Organization (WHO) Prequalification process.

Achieving WHO prequalification would not only meet domestic demand but also position Indonesia as a key player in the global vaccine supply chain. The Indonesian Food and Drug Control Agency (BPOM) has played a vital role in overseeing the entire process, from clinical trials and product standardization to production oversight and quality, safety, and efficacy evaluations. BPOM utilized an accelerated review mechanism to expedite the regulatory process without compromising scientific rigor or public safety.

“

Research, industry, and government are no longer walking alone, but strengthening each other in one innovation ecosystem.